The authors conclude that KRAS mutation status can be used to identify the subgroup of patients with irinotecan-refractory metastatic CRC who are most likely to respond to cetuximab.

The need to stratify the treatment of colorectal cancer with chemotherapy, based on whether or not KRAS mutations are present, exemplifies this,” concludes Roland Wolf, the study's principal ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS ... of patients with lung cancer or colorectal cancer.

KRAS mutations are a hallmark of PDAC, which is among the most difficult to treat cancers, and we believe TCR-T cell ...

A new case report was published in Oncotarget's Volume 15 on October 11, 2024, entitled "A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to ...